Business Context and Reporting Period
This Form 8-K is a current report filed by Stoke Therapeutics, Inc. (STOK) on February 13, 2026. The filing addresses Item 5.02 regarding compensatory arrangements for certain officers.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a discretionary bonus payment of $697,125 approved for the Chief Executive Officer.
Material Changes
The material event reported is the Board of Directors' approval of a discretionary bonus for Ian F. Smith, the Company's Chief Executive Officer. Mr. Smith did not participate in the 2025 annual bonus program due to his appointment timeline (interim CEO in March 2025, permanent CEO in October 2025). The bonus amount represents the full target annual bonus he would have received had he participated in the program, adjusted for corporate goal achievement determined to be 150% of target.
Guidance, Outlook, and Management Commentary
Management commentary indicates the bonus determination was based on the Company's clinical and financial performance following Mr. Smith's appointment. The filing does not contain forward-looking guidance, risk factors, contingencies, or unusual items beyond the executive compensation adjustment.
Investor Verification Checklist
- Verify the total cash impact of the $697,125 bonus on the Company's current liquidity position.
- Confirm the specific clinical and financial milestones achieved in 2025 that justified the 150% corporate goal achievement rating.
- Review the Company's 2025 Annual Report (10-K) to understand the standard bonus program structure and target amounts for executive compensation.
- Assess whether this discretionary payment aligns with the Company's stated capital allocation priorities given its development-stage status.